跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
HAEGARDA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
HAEGARDA
Authorized
STANDARD
HAEGARDA
csl behring canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
395f12dbb26b172f
Company
csl behring canada inc
Type
Standard
Approval Details
Approval Id
395f12dbb26b172f
Drug Approval Canada Name
HAEGARDA
Product Name
HAEGARDA
Status
Marketed
Status Date
2020-01-23
Original Market Date
2020-01-23
Din
02468077
Drug Class
Human
Dosage Form
Powder For Solution , Kit
Route Of Administration
Subcutaneous
Schedule
Schedule D
Ahfs
92:32.00
Atc Original
B06AC01 C1-INHIBITOR, PLASMA DERIVED
Atc Name
b 06 ac 01
Aig Number
0152746004
Company Name
csl behring canada inc
Company Address
350, 55 Metcalfe Street, Ottawa, Ontario, Canada, K1P 6L5
Active Ingredients
C1 ESTERASE INHIBITOR (HUMAN)
3000 UNIT / VIAL
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
395f12dbb26b172f
Type
Standard
Back to Health Canada Approvals